However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

Despite many advances made in the understanding of leukemia biology, therapy for acute myelogenous leukemia (AML) has remained essentially unchanged for 40 years and is, too often, debilitating ...